The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below, comes amid concerns over recent guidance that would reduce NIH funding to key research institutions.

-----------------------

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment.


As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research.


NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases.

While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return.


In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Marguron, Inc. licenses novel technology that could demonstrate an effective HIV functional cure

By Sheran Brown • February 20, 2025
February 19, 2025 [Atlanta, GA, Los Angeles, CA, and Miami, FL, USA] Marguron, Inc. (Marguron) and the University of Miami (UM) have entered into a global license agreement based on technology developed by Dr. Ronald C. Desrosiers, Dr. James Termini and colleagues at UM, and Dr. Anjie Zhen at the University of California, Los Angeles (UCLA). "We are pleased to have licensed the rights to these important technologies," said Vijai Mohan, CEO of Marguron. “The licensed intellectual property from UM and UCLA has the potential to prevent and treat HIV infections with a single intramuscular therapy using adeno-associated virus (AAV) gene therapy, generating a cocktail of powerful, broad-spectrum anti-HIV antibodies (bnAbs). Importantly, the improved technology appears to show lasting treatment effects, mitigating the persistent challenge of anti-drug antibody (ADA) formation.” In mice and non-human primates, a one-time intramuscular treatment was effective in producing continuous transgene expression thereby reducing HIV-1 viral loads to undetectable levels for a prolonged period without developing anti-drug antibodies, a historical roadblock in the implementation of gene-based delivery of bnAbs. Monkeys demonstrating persistent antibody expression have been followed for over five years, making clear the potential durability of the treatment. “We are delighted to partner with Marguron to advance the development of the Desrosiers Laboratory’s work for the benefit of persons affected by HIV/AIDS worldwide” said Norma Sue Kenyon, PhD, Vice Provost for Innovation at the University of Miami and Chief Innovation Officer at its Miller School of Medicine. Dr. Desrosiers, UM professor and a principal Founder of Marguron, stated “in a recent experiment using a proprietary immunomodulatory agent to inhibit ADA formation at the time of gene therapy administration, we successfully achieved therapeutic levels of anti-HIV monoclonal antibodies with potent neutralizing activity against a broad range of HIV isolates in five of five monkeys for more than six months. We are excited to work with an experienced team at Marguron to advance this remarkable technology for a ‘One and Done’ strategy for ART-free HIV remission. Our results were presented in full for the first time at the 2024 HIV-DART meeting in Los Cabos, Mexico.” About Marguron, Inc (www.marguron.com)  Marguron, Inc. is at the forefront of gene therapy-based cures for infectious and metabolic diseases, with an initial focus of preventing and treating HIV-1 infections. HIV/AIDS remains one of the most significant infectious disease threats. Globally, forty million people were living with HIV-1 in 2023, with 1.3 million new infections and 630,000 deaths from AIDS-related diseases. While advances in antiretroviral therapy (ART) have markedly improved the outlook for infected individuals in economically developed countries, the stark global statistics reflect the challenges with implementing ART, particularly in resource-limited countries. Even in the developed world, HIV/AIDS remains a disease that markedly impacts millions of lives, without access to an available functional cure. Marguron’s vision is to make reality that "one shot and you are protected for life". About University of Miami The University of Miami is one of America's top research universities located in one of the most dynamic and multicultural cities in the world. With more than $456 million in research and sponsored program expenditures annually, the University of Miami is a member of the prestigious Association of American Universities (AAU). Only 3 percent of four-year institutions in the nation are invited to join the AAU, which recognizes breadth and quality of research and scholarship. While the majority of this work is housed at the Miller School of Medicine, investigators conduct hundreds of studies in other areas, including marine science, engineering, education, and psychology. # # # MEDIA CONTACTS: Kai Hill khill@med.miami.edu c:-+1-305-332-3189 and Katie Roach info@marguron.com c: +1-404-490-0182
MORE POSTS
Share by: